↓ Skip to main content

Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial

Overview of attention for article published in BMC Medicine, January 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Citations

dimensions_citation
95 Dimensions

Readers on

mendeley
273 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial
Published in
BMC Medicine, January 2018
DOI 10.1186/s12916-017-0995-1
Pubmed ID
Authors

Natalie A. Grima, Shantha M. W. Rajaratnam, Darren Mansfield, Tracey L. Sletten, Gershon Spitz, Jennie L. Ponsford

Abstract

The study aimed to determine the efficacy of melatonin supplementation for sleep disturbances in patients with traumatic brain injury (TBI). This is a randomised double-blind placebo-controlled two-period two-treatment (melatonin and placebo) crossover study. Outpatients were recruited from Epworth and Austin Hospitals Melbourne, Australia. They had mild to severe TBI (n = 33) reporting sleep disturbances post-injury (mean age 37 years, standard deviation 11 years; 67% men). They were given prolonged-release melatonin formulation (2 mg; Circadin®) and placebo capsules for 4 weeks each in a counterbalanced fashion separated by a 48-hour washout period. Treatment was taken nightly 2 hours before bedtime. Serious adverse events and side-effects were monitored. Melatonin supplementation significantly reduced global Pittsburgh Sleep Quality Index scores relative to placebo, indicating improved sleep quality [melatonin 7.68 vs. placebo 9.47, original score units; difference -1.79; 95% confidence interval (CI), -2.70 to -0.88; p ≤ 0.0001]. Melatonin had no effect on sleep onset latency (melatonin 1.37 vs. placebo 1.42, log units; difference -0.05; 95% CI, -0.14 to 0.03; p = 0.23). With respect to the secondary outcomes, melatonin supplementation increased sleep efficiency on actigraphy, and vitality and mental health on the SF-36 v1 questionnaire (p ≤ 0.05 for each). Melatonin decreased anxiety on the Hospital Anxiety Depression Scale and fatigue on the Fatigue Severity Scale (p ≤ 0.05 for both), but had no significant effect on daytime sleepiness on the Epworth Sleepiness Scale (p = 0.15). No serious adverse events were reported. Melatonin supplementation over a 4-week period is effective and safe in improving subjective sleep quality as well as some aspects of objective sleep quality in patients with TBI. Identifier: 12611000734965; Prospectively registered on 13 July 2011.

X Demographics

X Demographics

The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 273 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 273 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 39 14%
Student > Ph. D. Student 25 9%
Student > Master 24 9%
Researcher 21 8%
Student > Doctoral Student 19 7%
Other 56 21%
Unknown 89 33%
Readers by discipline Count As %
Medicine and Dentistry 68 25%
Nursing and Health Professions 24 9%
Psychology 21 8%
Neuroscience 20 7%
Pharmacology, Toxicology and Pharmaceutical Science 11 4%
Other 30 11%
Unknown 99 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2022.
All research outputs
#1,358,919
of 25,389,532 outputs
Outputs from BMC Medicine
#961
of 4,005 outputs
Outputs of similar age
#31,762
of 451,275 outputs
Outputs of similar age from BMC Medicine
#18
of 50 outputs
Altmetric has tracked 25,389,532 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,005 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.5. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,275 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.